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Despite the recent success of gene-based complementation approaches for
genetic recessive traits, the development of therapeutic strategies for gain-of-
function mutations poses great challenges. General therapeutic principles to
correct these genetic defects mostly rely on post-transcriptional gene regulation
(RNA silencing). Engineered zinc-ﬁnger (ZF) protein-based repression of tran-
scription may represent a novel approach for treating gain-of-function
mutations, although proof-of-concept of this use is still lacking. Here, we
generated a series of transcriptional repressors to silence human rhodopsin
(hRHO), the gene most abundantly expressed in retinal photoreceptors. The
strategy was designed to suppress both the mutated and the wild-type hRHO
allele in a mutational-independent fashion, to overcome mutational heterogen-
eity of autosomal dominant retinitis pigmentosa due to hRHO mutations. Here we
demonstrate that ZF proteins promote a robust transcriptional repression of
hRHO in a transgenic mouse model of autosomal dominant retinitis pigmentosa.
Furthermore, we show that speciﬁcally decreasing the mutated human RHO
transcript in conjunction with unaltered expression of the endogenous murine
Rho gene results in amelioration of disease progression, as demonstrated by
signiﬁcant improvements in retinal morphology and function. This zinc-ﬁnger-
based mutation-independent approach paves the way towards a ‘repression–
replacement’ strategy, which is expected to facilitate widespread applications in
the development of novel therapeutics for a variety of disorders that are due to
gain-of-function mutations.
INTRODUCTION
Proof-of-concept studies and the recent success of clinical trials
are providing sound evidence for the use of gene-based
complementation therapeutic strategies to treat genetic reces-
sive traits (Aiuti et al, 2009; Bainbridge et al, 2008; Cartier et al,
2009; Hauswirth et al, 2008; Kaplitt et al, 2007; Maguire et al,
2009, 2008). Nevertheless, the design of effective therapeutic
strategies for dominant genetic traits still poses difﬁculties. The
common therapeutic approach to correct these genetic entities
relies on the silencing of gene expression. The main target of
genetic silencing strategies is the messenger RNA (mRNA)
transcript, the function of which can be inhibited by antisense-
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interfering (si)RNA-based and micro (mi)RNA-based,
approaches. In particular, RNA interference (RNAi) has great
promise for treating dominant diseases in both mutation-
dependent and -independent manners, through its efﬁciency of
mRNA transcript cleavage (LaVail et al, 2000; Lewin et al, 1998;
O’Reilly et al, 2007; Xia et al, 2004). A possible alternative to
such RNA-targeting approaches is the modulation of gene
expression at the transcriptional level, by using zinc-ﬁnger (ZF)-
based artiﬁcial transcription factors (ZF-ATFs) that can be
tailored to a desired DNA target sequence.
Artiﬁcial ZF proteins (ZFPs) are becoming a novel and
powerfultechnologicalplatformforbothgenemanipulationand
development of therapeutics (Jamieson et al, 2003; Pearson,
2008; Segal & Barbas, 2001). ZFPs are composed of a DNA-
binding domain (DBD) that is based on the Cys2His2 ZF scaffold
fused with a transcriptional regulation domain. Their modular
structure enablesboththesequentialassembling ofmultiple ZFs
togenerate DBDs withdifferenttarget speciﬁcities andthe useof
variouseffectordomainstoengineerATFsornucleases.Asingle
ZF domain consists of approximately 30 amino acids with a
simple bba fold that is stabilized by hydrophobic interactions
and the chelation of a single zinc ion. Each ZF module primarily
recognizes an overlapping 4-bp DNA sequence, where the last
base pair is the ﬁrst of the following target (the fourth base of
each target is on the opposite strand). The binding takes place
through key amino-acid residues, which can be exchanged to
generate ZF modules with different sequence speciﬁcities. To
obtain a DBD that is tailored to a unique target sequence in
mammalian genomic DNA (genome size in humans,
3.0 10
9bp), theoretically, a sequence longer than 16bp is
needed, and this can be achieved by consecutive linking of at
least six ZF modules.
To date, several functional ZF-ATFs have been generated to
modulate target gene expression in vitro (Bartsevich & Juliano,
2000; Beerli et al, 1998; Liu et al, 2001; Zhang et al, 2000);
however, none of the in vivo studies presented (Mattei et al,
2007; Rebar et al, 2002) have been aimed at silencing a disease
gene via vector-mediated somatic-gene transfer.
We designed a two-step repression–replacement strategy
(Cashman et al, 2005; Chadderton et al, 2009; Farrar et al, 2002;
Gorbatyuk et al, 2005; Kiang et al, 2005; O’Reilly et al, 2007; Xia
et al, 2004): (i) mutational-independent silencing of the human
rhodopsin (hRHO) gene (transcriptional silencing targeted to
both wild-type and mutated RHO alleles); and (ii) gene
replacement of the endogenous RHO copies by adeno-associated
virus (AAV)-vector-mediated photoreceptor gene transfer.
Considering that autosomal dominant retinitis pigmentosa
(adRP) is the most genetically heterogeneous inherited disease
inhumans,wedesignedthismutational-independentstrategyto
overcome the technical and economical magnitude of allele-
speciﬁc targeted-designed therapeutics. Indeed, in the case of
adRP, due to rhodopsin mutations, more than 150 allele-speciﬁc
silencing molecules would be required to silence each speciﬁc
mutation identiﬁed thus far (RHO gain-of-function mutations
account for 25–50% of the total autosomal dominant adRP
cases; (Inglehearn et al, 1998; Sohocki et al, 2001).
Here, we set out to determine whether transcriptional
repression by engineered ZFP technology represents a novel
therapeutic gene-silencing paradigm for the treatment of gain-
of-function mutations. To this end, we used a transgenic mouse
model of adRP harbouring a Pro347Ser (P347S) mutation in
hRHO.
We show that AAV-vector-mediated photoreceptor delivery
of a selected humanized ZF artiﬁcial transcriptional repressor
targeted to the mutated hRHO transgene in P347S adRP mice
results in signiﬁcant reduction of its expression, which in turn
leads to improved retinal pathology and function, which
validates the ﬁrst limiting step of the repression–replacement
strategy designed.
RESULTS
Design and generation of zinc-finger-based transcription
factors to control rhodopsin gene expression
To control RHO expression, we designed ZF-ATFs targeted to the
human rhodopsin promoter (hRHO-P). We ﬁrst scanned the
proximalhRHO-Ptoidentifyamenabletargetregions,applyingthe
following criteria: (i) exclusivity of the 18-bp DNA sequences in
the human genome; (ii) putative accessibility to the chromatin
environment [in proximity to known endogenous transcription-
factor binding sites; (Graslund et al, 2005)]; (iii) absence of
annotated polymorphisms; and (iv) divergence between the
human and murine rhodopsin promoter target sequences. We
selected 10 different continuous or discontinuous 18-bp target
sites within the proximal region of the hRHO-P (from 90 to  32,
relative to the transcription start site; Fig 1a and Table 1) that
fulﬁlled these four criteria. As individual ZFs typically bind 3 or
4bpofDNA,we generatedDBDs by assembling six-ZF arrays that
were directed to the selected 18-bp DNA sequences, using the
modularassemblymethod(http://www.zincﬁngertool.org;Beerli
et al, 1998; Mandell & Barbas, 2006; Segal et al, 1999). Due to the
lack of availability of ZFs for all possible triplets (Blancafort et al,
2003; Dreier et al, 2001, 2005, 2000; Segal et al, 1999) and to
enhanced DNA-binding afﬁnity (Kim & Pabo, 1998), we designed
10 ZF modules with two arms, each composed of three ZF units
(arm 1 encoding ﬁngers 1.2.3 and arm 2 encoding ﬁngers 4.5.6)
that were bridged together by linker peptides that allowed these
ZF modulestospan up to 10bp ofDNA gapsbetween their target-
recognition sites (Fig 1b). For gaps longer than 3bp, we used the
structured linker reported by Moore (Moore et al, 2001), whereas
for shorter gaps or continuous sequences, we used the ﬂexible
linker reported by Rebar (Rebar et al, 2002; Table 1). We next
fused the ZF DBDs to a nuclear localization signal, to a C-terminal
HA-tag, and to effector domains that included either the herpes
simplexvirus-basedtranscriptionalactivatorVP64domain(Seipel
et al, 1992; ZF transcriptional activators; ZF-As) or the human-
derived Kru ¨ppel-associated box (KRAB) repression domain
(Margolinetal,1994;ZFtranscriptionalrepressors:ZF-Rs;Fig1b).
In vitro screening of functional ZF-Rs
To select ZF-ATFs that are functional in hRHO-P transcriptional
control, we ﬁrst performed ﬁreﬂy luciferase reporter-gene
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the reporter gene driven by the human rhodopsin proximal
promoter ( 330 to þ32, relative to the transcription start site)
and the individual ZF-A. Two out of the 10 constructs
signiﬁcantly transactivated luciferase expression to levels
comparable to those obtained with a plasmid coding for the
endogenous rhodopsin transcription activator CRX (cone-rod-
homeobox-containing gene) (Chen et al, 1997) (Fig 1c; n¼5,
from three independent experiments; ZF-A2, p<0.01; ZF-A6,
p<0.01). When transfected with a luciferase-expression
plasmid containing the murine rhodopsin proximal promoter
region (harbouring several mismatches compared to the human
counterpart), none of the 10 constructs transactivated the
reporter gene expression. The results obtained for the selected
functional activators ZF-A2 and ZF-A6 are shown in Figure S1 of
Supporting Information. To evaluate ZFP-mediated transcrip-
tional repression, we assessed their down-regulation of CRX-
mediated transcription through triple transfection in HEK293
cells, which included the ZF-Rs, the CRX and the reporter
plasmids. Notably, ZF-R2 and ZF-R6, which contain the same
DBDs as ZF-A2 and ZF-A6, signiﬁcantly reduced luciferase
expression levels (81 and 64% repression relative to CRX
transactivation, respectively; Fig 1d; n¼5, from three inde-
pendent experiments; ZF-R2, p<0.001; ZF-R6, p<0.01),
similar to the repression obtained with the CRX DBD fused to
KRAB,whichwasusedasthepositivecontrol(Chauetal,2000).
Asafurthercontrol,theactivationandrepressionactivitieswere
completely abolished when the relative positions of the six
individual ZF units of the DBDs were exchanged (e.g. from
1.2.3–4.5.6 to 5.1.6–3.4.2; ZF-A6-shufﬂed and ZF-R6-shufﬂed;
Figure S2 of Supporting Information). In addition, electro-
mobility shift assays showed binding speciﬁcity of ZF-R2 and
ZF-R6 to the target promoter sequence in vitro (data not shown,
and Fig 1e, respectively).
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Figure 1. In vitro selection of functional ZF-Rs targeted to the human rhodopsin promoter.
A. DNAsequenceofhRHOproximalpromoterregion.Lines,relativepositionsofDNAsequencestargetedbythe10differentDBDs.Boxes,putativebindingsitesfor
known endogenous regulators of hRHO (Chen & Zack, 1996; Rehemtulla et al, 1996).
B. Schematic representation of the ZF transcriptional activator (ZF-A) and repressor (ZF-R).
C. Histogram showing the fold-changes (luciferase activity relative to the control vector; pGL3-hRHO-P) in HEK293 cells upon transfection of the transactivator
constructs (ZF-As). ZF-A2 and ZF-A6 significantly transactivated the luciferase expression. As a positive control, pGL3-hRHO-P was co-transfected with a
plasmid encoding for CRX, a known transactivator of rhodopsin.
D. Histogram showing the extent of repression relative to CRX transactivation of the luciferase activity mediated by ZF-Rs. ZF-R2 and ZF-R6 significantly
repressed the luciferase activity induced by CRX. As a positive control CRX DBD was fused to the KRAB repressor domain (CRX-KRAB).
E. Binding activity of ZF-R6 assayed by the electromobility shift assay. Representative sample showing evident shift when increasing amounts of nuclear extract
from HEK293 cells transfected with a plasmid coding for the ZF-R6 protein was incubated with the double-stranded specific target site probe (lanes 3 and 4).
The shift was not observed using nuclear extract from cells expressing ZF-R6-shuffled (lane 2). Specific binding was abolished upon addition of 10  or 100 
molar excess of cold probe to the mix (lanes 5 and 6), whereas no effects can be seen upon addition of 10  or 100  molar excess of an unspecific cold probe
(lane 7 and 8). The supershift is obtained by adding an antibody that recognizes the HA-tag of the ZF-R6 in the mix (lane 9).
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stem cells
To probe whether the two selected ZF-ATFs promote rhodopsin
transcriptional repression in the chromosomal context, we took
advantageofaninvitrosystemtodifferentiateretinalprecursors
(retinal stem cells; RSCs (Giordano et al, 2007)). Neurospheres
derived from the murine adult ocular ciliary margin can
differentiate in vitro into various retinal neuronal cell types,
including photoreceptor precursors that express rhodopsin, the
beta-subunit of phosphodiesterase-6 (PDE6b), and the cGMP-
gated channel (Cnga) (Sanges et al, 2006). We explanted
neurospheres from the adult P347S transgenic mouse. This
mouse model of adRP harbours a human rhodopsin transcrip-
tional unit (including 4kb of the proximal rhodopsin promoter
region) from apatient carrying aP347S mutation(Li etal, 1996),
in addition to the endogenous wild-type murine rhodopsin
alleles (mRho). Once differentiated into photoreceptor-like
(rhodopsin positive; Rhoþ) cells, P347S neurospheres under-
went apoptosis with kinetics similar to those observed in
another severe retinal-degeneration model [the rd-1 mouse;
(Sanges et al, 2006)]. Virtually all of the Rhoþ cells were also
TUNEL-positive 12 days after adding differentiating medium to
the P347S retinal cell precursors (Figure S3 of Supporting
Information). Thus, we expected that efﬁcient and speciﬁc
repression of the human mutated rhodopsin, combined with
preservation of the endogenous murine rhodopsin expression,
would result in rescue/survival of the photoreceptor precursors.
To this end, 7 days after adding the differentiating medium, we
transduced P347S retinal precursor cells with retroviruses
coding for the selected ZF-Rs (ZF-R2 and ZF-R6) or for ZF-R6-
shufﬂed as a negative control. Twelve days after the induction
of differentiation,  70% of the cells expressed rhodopsin (i.e.
were Rhoþ), 98% of which were also double positive (i.e. HAþ,
Rhoþ), conﬁrming that retroviruses can transduce retinal cell
precursors efﬁciently (Sanges et al, 2006). ZF-R2 and ZF-
R6 transduction produced signiﬁcant 77 and 92%
protection from cell death, respectively, whereas virtually all
of the ZF-R6-shufﬂed transduced cells underwent apoptosis
(Fig 2a, b and d; n¼2, from two independent experiments; ZF-
R2, p¼4.54 10
 11; ZF-R6, p¼1.18 10
 11). Confocal
images of triple-stained (HAþ, Rhoþ and TUNELþ) samples
conﬁrmed that only cells expressing ZF-R2 or ZF-R6 were
protected from apoptosis (Fig 2c).
Todetermine whether protection fromapoptosis wasthrough
speciﬁc repression of human rhodopsin transcription, we
measured hRHO mRNA levels 4 days after transduction.
Nonetheless, ZF-R2- and ZF-R6-transduced cells showed 51
and 88% reduction, respectively, of the hRHO transcript levels,
compared to hRHO levels in cells treated with ZF-R6-shufﬂed
(Fig 2e; n¼2, from two independent experiments; ZF-R2,
p<0.01; ZF-R6, p<0.01) after normalization with murine
rhodopsin, which was used to discriminate photoreceptor
precursor cells (Rhoþ cells) from those which were not induced
to express rhodopsin. These data show that ZFPs promote hRHO
transcriptional repression in a chromosomal context and that
this, in turn, can protect retinal progenitors of an adRP model
from apoptosis.
Delivery of ZF-Rs to murine photoreceptors decreases adRP
disease progression
The ZF-R6 construct, which provided robust hRHO transcrip-
tional repression and apoptosis protection, was selected for in
vivo experiments. We generated an AAV2/8 vector, as this is
currently considered to be most efﬁcient AAV delivery vehicle
for photoreceptor gene transfer (Allocca et al, 2007; Lebherz et
al, 2008; Natkunarajah et al, 2008; Stieger et al, 2008). This
AAV2/8 vector contained the ZF-R6 construct under the
photoreceptor-speciﬁc rhodopsin kinase (RHOK) promoter
element (Allocca et al, 2007) (AAV2/8-RHOK-ZF-R6). In
homozygous P347S mice, over-expression of the mutated
rhodopsin leads to the fast progression of retinal degeneration.
Indeed, by P21, only one row of photoreceptor nuclei was
detectable by histology (Figure S4 of Supporting Information).
Thus,todecreasehumanP347Srhodopsinexpressionlevels,we
crossed P347S mice with a wild-type C57BL/6 background. The
resulting progeny (P347S
þ/ ) showed milder retinal degenera-
tion (Figure S4 of Supporting Information). At P70, P347S
þ/ 
retinae still retained 5–6 rows of photoreceptor nuclei and
residual functionality, thus allowing evaluation of disease
progressionovertimebybothhistologyandelectroretinography
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Table 1. Sequences of the binding sites targeted by the artificial transcription factors in the hRHO proximal promoter
DBD No Target DNA sequence (50–30) Gap (bp) Strand Linker
a
1 gaacACCCCCAATctcccagATGCTGATT 7 þ A
2g a a CACCCCCAAtctcccaGATGCTGATt7 þ A
3 gaacACCCCCAATctcCCAGATGCTgatt 3 þ A
4 gaaCACCCCCAAtctccCAGATGCTGatt 5 þ A
5 cttgtggggGTTAGAGGGtCTACGACTAa1   B
6 cttgtGGGGGTTAGagGGTCTACGActaa 2   B
7 CTTGTGGGGGTTAGAGGGtctacgactaa None   B
8 CTTAGGAGGgGGAGGTCACt1 þ B
9 CTTAGGAGGggGAGGTCACT 2 þ B
10 gAATCCTCCCCCTCCAGTGa None   B
DBD, DNA binding domain.
The 18-bp target sequences are highlighted as bold capitals.
aLinker A: see Lebherz et al (2008); Linker B: see Farrar et al (2002).
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subretinal co-injection in P4 P347S
þ/  of 1 10
9 genome copies
(GC) of AAV2/8-RHOK-ZF-R6 and a vector coding for the
enhanced green ﬂuorescent protein (EGFP; AAV2/1-CMV-
EGFP), to identify the transduced retinal area. The contralateral
eye received a mix of AAV2/1-CMV-EGFP and AAV2/8-RHOK-
EGFP vectors as control. Western blotting showed expression of
the ZF-R6 protein in the retina 12 days post-injection (P18,
before photoreceptor degeneration; Fig 3a). Quantitative real-
time polymerase chain reaction (PCR) analysis demonstrated
that the EGFP-positive portion of the retinae treated with AAV2/
8-RHOK-ZF-R6 showed signiﬁcant,  26%, reduction in the
hRHO transcript levels relative to the endogenous mRho,
compared to the contralateral EGFP-treated retinae (Fig 3b;
n¼9, from two independent littermates; p<0.01). In contrast,
the expression proﬁles of three photoreceptor-speciﬁc genes
were unchanged (Fig 3b; n¼4).
We next evaluated the ability of AAV2/8-RHOK-ZF-R6 to
impact on P347S photoreceptor disease progression. As we
noted that there was variability in the retinal function assessed
by recording the electrophysiological response of the retina to
increasing light intensities (ERG) among different littermates,
Report
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Figure 2. ZFP-mediated repression of rhodopsin in retinal stem cells.
A. Representative rhodopsin and TUNEL staining of RSCs from the P347S mouse following differentiation for 7 days, then transduction with retroviruses
containing ZF-R2, ZF-R6 and ZF-R6-shuffled, with analysis after a further 4 days. ZF-R2 and ZF-R6 transduction prevented apoptosis (TUNELþ; green) in Rhoþ
cells (Red). ZF-R6-shuffled did not protect photoreceptor-like cells from death.
B. Representative immunofluorescence showing the specific protection effects of the ZF-Rs. Photoreceptor-like cells were protected from apoptosis (TUNELþ;
red) when transduced (HAþ cells; green) with ZF-R2 and ZF-R6 (arrows). No protection was seen for cells transduced with ZF-R6-shuffled.
C. RepresentativeconfocalimagesshowingthatRhoþ(red)andHAþ(blue)cellsareprotectedfromapoptosis(TUNELþ;green)onlywhentransducedwithZF-R2
and ZF-R6.
D. Histogram showing quantification of the data reported in (A).
E. Histogram from quantitative RT-PCR analysis of hRHO mRNA levels in transduced cells. The values were normalized with photoreceptor-specific mRho
transcript levels, which were used as a marker to normalize the number of photoreceptor precursor cells from those that were not induced to express
rhodopsin and were dying at the time of analysis.
 p<0.01;
  p<0.001, as statistically significance differences (t-test).
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Figure 3. AAV-mediated photoreceptor ZFP gene transfer reduces the severity of adRP retinal dystrophy.
A. Representative Western blot with an anti-HA antibody of the lysates from P347S retinae (P18) injected with AAV2/8-RHOK-ZF-R6 at P4. Lane 1: HEK293 cells
transfected with a plasmid encoding for ZF-R6; lane 2: P347S retinal extracts transduced with AAV2/1-CMV-EGFP and AAV2/8-RHOK-EGFP; lane 3: P347S
retinal extracts transduced with AAV2/8-RHOK-ZF-R6 and AAV2/1-CMV-EGFP. Actin expression was used for normalization (anti-actin antibody).
B. Histogram from quantitative RT-PCR analysis on P18 retinae transduced at P4 with AAV2/8-RHOK-ZF-R6 and AAV2/1-CMV-EGFP. Specific down-regulation, by
26%, of human rhodopsin transgene expression was measured in the treated eyes (white bars) compared to the control-injected eyes (black bars).
Photoreceptor specific gene expression levels (murine rhodopsin, peripherin, PDE6b and Cnga) remained unaltered in treated and control retinae (values
normalized versus endogenous GAPDH transcript levels).
  p<0.05, as statistically significance difference between ZF-R6 and EGFP treated eyes of the same
animals (t-test).
C. Electrophysiological responses of retina recorded byERG analysis, onP347S
þ/  mice injected subretinally with AAV2/8-RHOK-ZF-R6 and AAV2/1-CMV-EGFP or
AAV2/1-CMV-EGFPandAAV2/8-RHOK-EGFPatP30.Theamplitudesrepresentretinalresponsesevokedbyincreasinglightintensitiesunderscotopic(dimlight)
and photopic (bright light) conditions. B-wave amplitudes before treatment (base-line: P30; open triangles, n¼34 eyes, 17 animals) and after treatment (P90;
filled circles, n¼16eyes,AAV2/8-RHOK-ZF-R6treated animals;open circles, n¼15 eyes,AAV2/8-RHOK-EGFP treated animals). Sixty daysafter vectordelivery,
the electrophysiologic responses of the retina were preserved in ZF-R6-treated eyes (black circles) compared to control contralateral EGFP injected eyes (open
circles).
 p<0.01;
  p<0.001, as statistically significance differences between EGFP control eyes (P90) and base-line responses (P30).
D. Representative indirect ophthalmoscopy of retinal fundus. Fluorescent EGFP expression indicates the extension of retinal exposure after AAV vector
administration (P90 P347S retina co-injected with AAV2/8-RHOK-ZF-R6 and AAV2/8-RHOK-EGFP).
E. Representative immunofluorescence histological analysis of AAV2/8-RHOK-ZF-R6 treated retina showing the EGFP-positive retinal portion transduced (right;
dotted square, selected field at higher magnification, 20 ; co-injection of AAV2/8-RHOK-ZF-R6 and AAV2/8-RHOK-EGFP). This treatment resulted in partial
preservation of photoreceptor cell nuclei, as compared to EGFP-negative area (left; dotted square as before).
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contextually measure base-line ERG parameters and treat the
animals subretinally. We performed subretinal injections of
1 10
9GC of AAV2/8-RHOK-ZF-R6 in three independent 1-
month-old P347S
þ/  littermates (P30; for a total of 17 animals,
34 eyes: 17 RHOK-ZF-R6 and 17 RHOK-EGFP eyes), with the
pairedeyeofthe sameanimals receivingthe samevectordoseof
AAV2/8-RHOK-EGFP. At 60 days following this subretinal
vector administration (P90), the eyes that received AAV2/8-
RHOK-ZF-R6 showed preservation of ERG responses, as
compared to the control EGFP-treated eyes of the same animals,
in which the degeneration led to a  40% reduction in the
b-wave maximum amplitude (Table 1 of Supporting Informa-
tion, Fig 3c). In addition, histological analysis of mice at P90–
100 demonstrated that the ZF-R6-transduced portion of the
retina (typically 30–50% of the retina, Fig 3e), was associated
with partial protection of the photoreceptor degeneration in
seven eyes out of the nine analysed (Fig 3d and e).
Finally, to evaluate potential toxicity on retinal function of a
healthy mouse retina due to ZF-R6 treatment, we injected
AAV2/8-RHOK-ZF-R6 subretinally in a cohort of 10 C57BL/6
animals. Two months after vector delivery, no histological
abnormalities or reductions in either the a-waves or b-waves
were seen for the treated eyes, as compared to untreated
parental eyes, thus supporting the safety of this approach
(Figure S5 of Supporting Information).
DISCUSSION
In the present study, we have demonstrated that photoreceptor
delivery of an AAV2/8 vector containing artiﬁcial ZF transcrip-
tional repressors (ZF-R6) targeted to the hRHO promoter can
repress hRHO transgene over-expression, and this, in turn, was
associated with improvement in photoreceptor disease in the
P347S mouse model of adRP. Our ﬁndings extend the possible
uses of artiﬁcial ZF-based DBPs as novel therapeutics for the
treatment of dominant diseases.
A different technological platform based on RNAi was ﬁrst
used in vivo to silence a dominant allele of ataxin-1 for the
treatment of spinocerebellar ataxia type 1 in a mutational-
independent manner; this approach was then applied to other
mouse models of human disease, including the P347S adRP
mouse (O’Reilly et al, 2007; Xia et al, 2004). Thus, based on the
data presented here, transcriptional (artiﬁcial ZFP technology) or
post-transcriptional(RNAi)silencingstrategiescanbeconsidered
as alternatives to one another; however, in the light of the
different molecular mechanisms underlying these two silencing
strategies(promoterbindingandtranscriptioninhibitionofZFvs.
enzyme-like degradation of mRNA by RNAi), a side-by-side
comparison will be necessary to determine which of these two
systems is the safest and the most efﬁcacious. Moreover, as well
as the off-target silencing events that will potentially set the
hurdles for the development of a safe ZFP-based or RNAi-based
system, studies have shown that high levels of siRNAs can cause
cellular toxicity through various mechanisms (Boudreau et al,
2009; Grimm et al, 2006). Also, an attractive and therapeutically
valuable feature of ZFPs is the possibility to control their
expression levels through the use of inducible promoter systems,
which have not yet been optimized for the control of RNAi-based
repression systems. Indeed, a key safety and efﬁcacy element for
the success ofsilencing strategiesrelies onthe ﬁne-tuningcontrol
of the expression levels of the repressor system.
The transcriptional, mutational-independent strategy used in
the present study is aimed at overcoming the heterogeneity of
mutations in the RHO gene. Indeed, the design of mutation-
speciﬁc silencing molecules is technically, and economically,
particularly challenging, considering that: (i) retinitis pigmen-
tosa is widely thought to be the most genetically heterogeneous
disorder in man (Wright et al, 2010); and (ii) over 150 dominant
mutations in rhodopsin are known to date (OMIN database
180380). As has been previously suggested (e.g. RNAi-mediated
suppression and replacement of human rhodopsin in vivo;
(O’Reilly et al, 2007), we propose here to apply a general
strategy that is based on the repression of both the mutated and
the wild-type alleles, and the simultaneous replacement of the
endogenous gene copies with the exogenous vector-delivered
gene [repression–replacement strategy; (O’Reilly et al, 2007)].
In the present study, the ZF-Rs acted as transcriptional hRHO-
speciﬁc silencers, whereas the endogenous copies of murine
Rho alleles functioned as a replacement gene. Thus, one future
development should be the use of an amenable mouse model
(ideally harbouring both a mutated and a normal hRHO gene on
a mRho-knock-out background) to determine whether down-
regulation of both alleles together with simultaneous replace-
ment with a hRHO transgene (under the transcriptional control
of a promoter insensitive to the ZF-R) will result in phenotypic
rescue. Although this needs to be tested, the feasibility of this
proposed approach is based on the following considerations: (i)
we have demonstrated the ability to down-regulate the levels of
transcription somatically (via AAV-vector delivery), which
represents the major limiting step in the strategy; (ii) the
therapeutic levels of transcriptional silencing result in pheno-
type amelioration (26%), and thereby the levels of RHO
necessary for replacement appear feasible to achieve, consider-
ing the proof-of-concept obtained with the gene-replacement
approach in different animal models of retinal degeneration
[recently also in Rho
 /  mice; (Chadderton et al, 2009)], as well
as clinical trials (Bainbridge et al, 2008; Hauswirth et al, 2008;
Maguire et al, 2008); and (iii) there is the possibility to
incorporate two genes into the same vector (both the silencing
and the replacement constructs in our case), as this has been
demonstrated in AAV vectors by us and others (Allocca et al,
2007; Nguyen et al, 2007). Indeed, a vector that incorporates
both the artiﬁcial ZF-based repressor and the replacement gene
will ensure their simultaneous and balanced silencing and
repression action in the same transduced photoreceptors [e.g.
with bidirectional promoters allowing the coordinated expres-
sionofthetwotransgenes;(Amendolaetal,2005)].Moreover,it
has been shown that both high and low rhodopsin expression
levels can be deleterious to rod function, which suggests that
tightregulationofrhodopsinexpressionlevelsisrequiredforthe
successful application of any retinal repression–replacement
strategy.
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switch the repressor with an activator domain (maintaining the
same DBD) to also treat dominant diseases that are due to
haploinsufﬁciency.
The results from the present study demonstrate that the
novel and generally applicable mutational-independent
strategy based on artiﬁcial ZFPs allows transcriptional control
of an endogenous causative gene and has therapeutic
relevance for the treatment of diseases due to gain-of-function
mutations.
MATERIALS AND METHODS
Rational design of zinc-finger-based artificial
transcription factors
DBDs targeted to 10 different target sites in the hRHO promoter (Table
1) were obtained using the web-based Zinc Finger Tools [http://
www.zincfingertools.org; (Mandell & Barbas, 2006)]. These were
composed of two arms, each of which recognized a 9-bp half-target
site, and they were fused together through a linker sequence, to bridge
the gap sequence. We used two different linkers according to the
lengths of the gaps: for gaps longer than 3bp (target sites from 1 to 4),
we used a complex structured linker, as reported by Moore [(Moore et
al, 2001); GRSSVESACVTSVLVALLPATSAPTQVSG], while for longer gaps
(target sites from 5 to 10), we used a flexible linker, as described by
Rebar [(Rebar et al, 2002); QNKKGGSGDGKKKQHI]. We optimized the
corresponding DNA sequences to facilitate the subsequent cloning
steps, and purchased these as transgenes in the pLS-standard vector
(TOP Gene Technologies, Quebec, Canada). After the in vitro selection
steps, we purchased an additional DBD with the fingers of DBD
number six shuffled (from 1.2.3–4.5.6 to 5.1.6–3.4.2) to be used as a
negative control for a total of 11 DBDs. All of the DBDs were flanked by
a ClaI and an XbaI site at the 50 and 30 ends, respectively.
DBD number 1 was purchased as a complete protein fused at the
N-terminal with the repressor domain KRAB (Kru ¨ppel-associated box,
DAKSLTAWSRTLVTFKDVFVDFTREEWKLLDTAQQILYRNVMLENYKNLVSL-
GYQLTKPDVILRLEKGEEPWLVEREIHQETHPDSETAFEIKSSV) and the nu-
clear localization signal (PKKKRKV) from the SV40 large T antigen, and
fused at the C-terminal with the HA-tag (YPYDVPDYAS). Also, DBD
number 2 was purchased as a complete protein, but fused at the
C-terminal with the nuclear localization signal, the activator domain
VP64 (tetrameric repeat of herpes simplex VP16 minimal-activation
domain, GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGS-
DALDDFDLDMLIN) and the HA-tag. In the two proteins, the DBDs
can be exchanged through a double digestion with the restriction
endonucleases ClaI and XbaI.
The 11 different transcription activators (ZF-As) and repressors (ZF-Rs)
were inserted in the pAAV2.1-CMV-EGFP NotI and HindIII sites,
downstream of the cytomegalovirus (CMV) promoter, by removing the
EGFP coding sequence for transfection experiments. For AAV prepara-
tions, ZF-R6 was inserted in the pAAV2.1-RK-EGFP NotI and HindIII
sites, downstream of the RHOK promoter, by removing the EGFP
coding sequence. For retrovirus preparations used in RSC experiments,
coding sequences of ZF-R2, ZF-R6 and ZF-R6-shuffled were cloned in
the LXSN plasmid EcoRI and HindIII sites downstream of the CMV
promoter.
Reporter constructs
Luciferase reporter plasmids were generated from the pGL3-Basic
vector (Promega, Madison,WI, USA), by cloning the proximal upstream
regions of the human or murine rhodopsin gene (see Materials and
Methods Section of Supporting Information).
Screening of the functional ZF-ATFs in human cells by
transient transfection
HEK293 cells were plated in six-well plates at a density of
400,000cells/well. Twenty-four hours later, the cells were co-
transfected using FUGENE 6 (Roche, Basel, Switzerland), following
the manufacturer instructions. Transfection cocktails included 200ng
reporter plasmid (or pGL3basic as a negative control), 300ng ZF-ATF,
300ng of a plasmid encoding for murine CRX (alone, as a positive
control in transactivation assays, or in combination with the ZF-Rs, for
repression assays) and 10ng Renilla luciferase reporter plasmid
control (Promega), to normalize for transfection efficiency.The amount
of DNA was kept constant by adding pAAV2.1-TBG-EGFP, to a total of
1mg. Cells were harvested 48h after transfection in 1  PLB Lysis
Buffer (Promega). Firefly and Renilla luciferase activities were
measured in a GloMax
TM luminometer (Promega), using the Dual
Luciferase Reporter Assay System (Promega).
Electromobility shift assay
Electromobility shift assays were performed using Lightshift Chemi-
luminescent Electromobility Shift Assay kits (Pierce), following the
manufacturer instructions. The detailed procedure is available in the
Materials and Methods Section of Supporting Information.
AAV vector production and purification
AAV vectors were produced by the TIGEM AAV Vector Core using
pAAV2.1-RK-ZF-R6 and pAAV2.1-CMV-EGFP. Recombinant AAV8
viruses were produced by triple transfection of HEK293 cells followed
by CsCl2 purification of the vectors, as previously described (Auricchio
et al, 2001). For each viral preparation, physical titers (GC/ml) were
determined by both PCR quantification using TaqMan (Perkin-Elmer,
Life and Analytical Sciences, Inc.) and by dot-blot analysis.
RNA preparation and measurement of rhodopsin transcript
levels by real-time PCR
RNAs from tissues and cells were isolated using TRIZOL reagent
(Invitrogen), according to the manufacturer protocol. cDNA was
amplified from 500ng isolated RNA using SuperScript
TM III First-
Strand Synthesis (Invitrogen), as indicated in the manufacturer
instructions. Transcript levels of human and murine rhodopsin were
measured by real-time PCR using the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA) and the
following primers: hRho_forward 50...CCGGCTGGTCCAGGTACAT...30
and hRho_reverse 50...TTGTTGACCTCCGGCTTGAG...30; mRho_forward
50...TGTTGAACAAGCAGTTCCGGA...30 and mRho_reverse
50...TCGTCATCTCCCAGTGGATTC...30. The PCRs with cDNA were carried
out in a total volume of 25ml, using 12.5ml SYBR Green Master Mix
(Applied Biosystems) and 400nM primers under the following
conditions: preheating, 508C for 2min, and 958C for 10min; cycling,
40 cycles of 958C for 15s and 608C for 1min. All of the reactions were
standardized against murine GAPDH using the following primers:
mGAPDH_forward 5-0...CTTCACCACCATGGAGAAGGC...-30 and
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expression levels of photoreceptor specific genes (Peripherin, PDE6b
and Cnga) we used the following primers: for Peripherin: mPeriph.for-
ward 50-CGGGACTGGTTCGAGATTC-30 and mPeriph.reverse 50-ATC-
CACGTTGCTCTTGATGC-30;f o rPDE6b:P D E 6 b.forward 50-
TGAAGATGAAGATGTTTTCACG-30 and PDE6b.reverse 50-
CTCTGCGTGTCTCACAGTTG-30; for Cnga: Cnga.forward 50-ACTCGTA-
CAAAAGGCGAGGAC-30 and Cnga.reverse 50-
CTTTGTTGCTGCTGTTGTTGAC-30. Each sample was analysed in tripli-
cate in two-independent experiments.
Retinal stem cell culture and analysis
All procedures on mice (including their euthanasia) were performed in
accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research, and with institutional guidelines for
animal research.
RSCs were isolated from adult P347S mice and incubated for 5 days,
until floating spheres formed in the serum-free medium (DMEM-F12
with 0.6% glucose and N2 hormone mix) containing 20ng/ml basic
FGF supplemented with 2mg/ml heparin (Sigma, Milan, Italy), as
previously described (Sanges et al, 2006). The retinal floating spheres
were allowed to differentiate in DMEM-F12 supplemented with 1%
foetal bovine serum (Gibco, San Giuliano Milanese, Italy), in eight-well
glass slides that were coated with extracellular matrix (Sigma). The
analysis was performed 12 days after induction of differentiation.
Apoptotic nuclei were revealed using the TdT-dUTP terminal nick-end
labelling kit (TUNEL, Roche Diagnostics, Monza, Italy), according to the
manufacturer protocol. For immunofluorescence staining of RSCs, see
Materials and Methods Section of Supporting Information.
Animal model, vector administration and tissue collection
All procedures were performed in accordance with institutional
guidelines for animal research and all of the animal studies were
approved by the authors. P347S
þ/þ animals for breeding were kindly
provided by Dr. G. Jane Farrar (Smurfit Institute of Genetics, Trinity
College Dublin, Dublin, Ireland) and were bred in the animal facility
of the Biotechnology Centre of the Cardarelli Hospital (Naples, Italy)
with C57BL/6 mice (Charles Rivers Laboratories, Calco, Italy), to
obtain the P347S
þ/  mice. At P4, the animals were anesthetized on
ice and injected subretinally in the right eye with 1ml AAV2/8-
RHOK-ZF-R6 vector (6.3 10
12GC/ml) and 1ml of AAV2/1-CMV-
EGFP (6.0 10
12GC/ml) in a mixture, whereas the contralateral
(control) eye received the same dose of AAV2/1-CMV-EGFP and
A A V 2 / 8 - R H O K - E G F Pv e c t o r sa sam i x t u r e .T h em i c ew e r es a c r i f i c e da t
post-natal day 18 or at 1 month of age (P18 or P30). For
morphological studies, the eyecups were harvested, fixed by
immersion in 4% paraformaldehyde, and then embedded in OCT
(Kaltek) The detailed procedures for the histological analysis are
given in the Materials and Methods Section of Supporting
Information. For RNA extractions, the isolated retinae were removed
and snap-frozen in liquid nitrogen, and then treated as described in
the above RNA preparation section.
Indirect ophthalmoscopy
The mice were anesthetized with avertin, and their pupils were
dilated with topically applied 1% tropicamide. Indirect ophthalmo-
scopy was performed using a 90-diopter lens. Photographs were
taken with a Kowa Genesis camera (Keeler Instruments, Broomall,
PA, USA).
Electroretinogram measurements
ERGs were performed at P30, P70 and P90. The detailed procedures
are given in the Materials and Methods Section of Supporting
Information. Amplitudes of the a-waves and b-waves were plotted as
functions of increasing light intensities.
Statistics
The data are expressed as means standard error of the mean (s.e.m.),
as indicated, and compared by two-tailed Student’s t-tests, and two-
sample equal variance.
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The paper explained
PROBLEM:
Autosomal dominant forms of Retinitis Pigmentosa (adRP) are
incurable progressive inherited retinal degenerations, which
inexorably lead to blindness. The major hurdles to design
effective therapeutic strategies for these diseases are: the
genetic heterogeneity (a number of distinct mutations affect
numerous individual gene), and the tools to turn off mutated
genes are inefficient and difficult to be delivered specifically and
efficiently to diseased cells.
RESULTS:
We generated artificial zinc-finger transcriptional repressors
(ZFRs) capable to bind DNA regulatory regions controlling
rhodopsin gene (RHO) expression, one of the most frequently
genes mutated in adRP. To overcome genetic heterogeneity we
designed ZFRs that silence RHO in a mutational-independent
fashion. We showed that adeno-associated (AAV) viral vector-
mediated delivery of ZFR to photoreceptors of a mouse model of
adRP that carries a dominant RHO mutation, result in robust
down-regulation of RHO and that this in turn results in
improvement of disease progression.
IMPACT:
OurresultsarethefirsttodemonstratethatZFtechnologycanbe
exploited to induce transcriptional gene silencing of an
endogenous gene via viral vector-mediated delivery in vivo. This
proof-of-concept study holds promise for the development of
novel therapeutics for adRP-associated with any rhodopsin
mutation and a variety of other inherited disorders.
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